Showing posts with label non-experts. Show all posts
Showing posts with label non-experts. Show all posts

Wednesday, January 17, 2018

Drug design: My latest paper explained without the jargon

Our latest paper has appeared in the latest issue of Chemical Science. It's ultimately related to making better drugs so first some background.

Background
Making complex drug candidates for testing is usually done in several steps where new chemical groups are added at each step. There are usually several reactive atoms and the challenge is to predict the most reactive one. This is currently done mostly by chemical intuition and related literature examples – an approach that often fails, which contributes significantly to the cost of making new drugs. So, there is a need for a fast, yet powerful and easy-to-use tool to predict the most reactive atom in a molecule. 

The New Study
For this study we collaborated with the pharmaceutical company Lundbeck A/S to develop a user-friendly tool to predict the most reactive atoms for one of the most often used chemical reaction within drug design.  We compared our predictions against published results for more than 500 different kinds of molecules and found that we made correct predictions in 96% of the cases.
We have made the software is available free to anyone and also made an easy-to-use web interface at regiosqm.org.  We are now working on extending the method to other types of reactions.




This work is licensed under a Creative Commons Attribution 4.0

Tuesday, February 28, 2017

Biotechnology and drug-design: My latest paper explained without the jargon

Our latest paper has just appeared in the open access journal Chemical Science. It's ultimately related to biotechnology and drug design so first some background.

Background
Most biotechnology and medicine involves proteins in some way. Many diseases involve mutations that alter the function of proteins, most drugs are molecules that bind to proteins and inhibit their actions, and a large part of industrial biotechnology involves making new types of proteins such as enzymes. Like with everything else, it is easier to deal with proteins of you know what they look like but protein structure determination can be very difficult and we don't know what many important proteins actually look like.

The most popular way of determining protein structure is a technique called x-ray crystallography where you basically take an x-ray of a crystal made from the protein. Unfortunately, it can be very difficult or impossible to grow crystals of some proteins and if you can't get the protein to crystallise you can't use x-ray crystallography to find the structure.  The other main way for determining protein structure is a technique called NMR spectroscopy where you basically take an MRI of a solution containing the protein. The advantage is that there is no need for crystallisation, but the disadvantage it that it is difficult to extract enough information from the "NMR-MRI" go get a good structure.

The "NMR-MRI" of a protein actually provides a unique fingerprint of each protein so in principle all one has to do is generate a lot of possible structures of a protein, compute the NMR fingerprint for each, and compare to the measured fingerprint. The structure with the best fingerprint match should be the correct protein structure.  The questions are how to best generate the structure and how to best predict the NMR fingerprint using the structure.

The New Study
In 2015 we published a new method for predicting NMR fingerprints and in the paper that just got published we combined it with a method for generating a lot of protein structures. We started with known x-ray structures and generated millions of relatively small variations of the structure and found the structure with the best match.  We started from a known structure to answer the question: what is the best match we can hope for? The answer is: not perfect but good enough.  Now that we know this the next step will be to start with a structure we know is wrong and see if the program can find the right structure.  Also, our NMR fingerprint method does not generate fingerprints for all parts of the protein so we need to improve the model as well.




This work is licensed under a Creative Commons Attribution 4.0

Saturday, January 28, 2017

Drug design: My latest paper explained without the jargon

Our latest paper has just appeared in the Journal of Physical Chemistry A.  If you don't have access to this journal you can find a free version of an earlier draft here. It's ultimately related to making better drugs so first some background.

Background
Designing new drugs currently involves a lot of trial-and-error, so you have to pay a lot of smart scientists a lot of money for a long time to design new drugs - a cost that is ultimately passed on to you and I as consumers.  There are many, many reasons why drug design is so difficult. One of them is that we often don't know fundamental properties of drug-candidates such as the charge of the molecule at a given pH. Obviously, it is hard to figure out whether or how a drug-candidate interact with the body if you don't even know whether it is postive, negative or neutral.

It is not too difficult to measure the charge at a given pH, but modern day drug design involves the screening of hundreds of thousands of molecules and it is simply not feasible to measure them all. Besides, you have to make the molecules to do the measurement, which may be a waster of time if it turn out to have the wrong charge. There are several computer programs that can predict the charge at a given pH very quickly but they have been known to fail quite badly from time to time.  The main problem it that these programs rely on a database of experimental data and if the molecule of interest doesn't resemble anything in the database this approach will fail.

Last year we developed a "new" method for predicting the charge of a molecule that relies less on experimental data but it fast enough to be of practical use in drug design. We showed that the basic approach works reasonably well for small prototypical molecules and we even tested one drug-like molecule where one of the commercial programs fail and show that our new method performs better (but not great). 

The New Study
We test the method on 48 drug molecules and show that it works reasonably well.  It is not quite as accurate as the methods that rely on experimental data, but this is probably because many of the molecules we test are in the databases that the programs use.  But we felt we had to test these molecules first because they are some of the first molecules other users will try to test the method. The next step is to test the method on molecules where some of the existing methods perform poorly. We also have to think about how best to make this method available to researchers who are acutually doing the drug design.



This work is licensed under a Creative Commons Attribution 4.0 

Thursday, August 11, 2016

Drug design: My latest paper explained without the jargon

Our latest paper has just appeared in the open access journal PeerJ. It's ultimately related to making better drugs so first some background.

Background
Designing new drugs currently involves a lot of trial-and-error, so you have to pay a lot of smart scientists a lot of money for a long time to design new drugs - a cost that is ultimately passed on to you and I as consumers.  There are many, many reasons why drug design is so difficult. One of them is that we often don't know fundamental properties of drug-candidates such as the charge of the molecule at a given pH. Obviously, it is hard to figure out whether or how a drug-candidate interact with the body if you don't even know whether it is postive, negative or neutral.

It is not too difficult to measure the charge at a given pH, but modern day drug design involves the screening of hundreds of thousands of molecules and it is simply not feasible to measure them all. Besides, you have to make the molecules to do the measurement, which may be a waster of time if it turn out to have the wrong charge. There are several computer programs that can predict the charge at a given pH very quickly but they have been known to fail quite badly from time to time.  The main problem it that these programs rely on a database of experimental data and if the molecule of interest doesn't resemble anything in the database this approach will fail. The paper that just got published is a first step towards coming up with an alternative.

The New Study
We present a "new" method for predicting the charge of a molecule that relies less on experimental data but it fast enough to be of practical use in drug design. The paper shows that the basic approach works reasonably well for small prototypical molecules and we even test one drug-like molecule where one of the commercial programs fail and show that our new method performs better (but not great).  However, we have to test this new method for a lot more molecules and in order to do this we need to automate the prediction process, which currently requires some "manual" labor, so this is what we're working on now.



This work is licensed under a Creative Commons Attribution 4.0 

Tuesday, May 3, 2016

Enzyme design: My latest paper explained without the jargon

Our latest paper has just appeared in the open access journal PeerJ.  It's ultimately related to making better enzymes so first some background.

Background
Enzymes are proteins that make certain chemical reactions go faster and nearly every complex molecule in your body is made by, or broken down by, enzymes.  But people have also started using enzymes in commercial products, for example in washing powder to break down oily stains at lower temperatures. This saves money on heating the water and, being proteins, the enzymes are biodegradable. So there is a lot of interest in designing new enzymes that build or break down new molecules efficiently. For example, there is a rather large company (Novozymes) near Copenhagen that does nothing but design, produce, and sell enzymes on an industrial scale.

Designing new enzymes currently involves a lot of trial-and-error, so you have to pay a lot of smart scientists a lot of money for a long time to design new enzymes - a cost that is ultimately passed on to you and I as consumers. My long-term goal is to reduce the amount of trial-and-error by writing a computer program that can predict what changes you have to make to improve the enzyme before you ever make it in the lab.

I've had some modest success with a prototype program some years ago (you can find the papers here and here) for one enzyme.  But one of the many things we don't know is whether the method we base our approach on will work at all for other types of enzymes. The paper that just got published is a first small step in figuring this out.

The New Study
We've collected data for five other enzymes from other published papers that we trust reasonably well and tested two methods that are fast enough to design enzymes - one is the same method we used a few years ago and the other is a newer one that wasn't available to us before now.  The conclusion of our study is that the methods seem to work well enough for all but one system, and this system is different for the two methods.  This suggests that we can't just base future work on one method. We have to have both ready in case one of them fail.  We need to repeat the study for many other types of enzymes - I would say at least 15-20 more - and we need to improve the quality of the data so that we trust it completely, rather than "reasonably well".  In the paper we have extended an open invitation to other scientists to contribute to this effort.




This work is licensed under a Creative Commons Attribution 4.0